Editor's Note: Since entering the market in 1982, Louis Navellier predicted nearly every twist and turn in U.S. stocks... from Black Monday and the dot-com crash... to the Enron fraud, the housing crisis, and the rise of Nvidia in 2005. That's why the New York Times calls Louis Navellier "an icon among growth investors." Today, he's airing what could be the biggest prediction of his career – and he's putting $358 million of his own firm's money behind it.
Dear Reader,
I recently visited Mar-a-Lago...
And now I'm prepared to put my reputation on the line.
Since 1998, my proprietary system would've returned 13,126% in backtests.
(That's 13X the S&P. And 106 times the average investor, according to JP Morgan.)
There's a reason Forbes crowned me "the king of quants."
However, one investment I just uncovered could be my biggest winner of all...
It involves President Trump's plan to do whatever it takes to lead the world in artificial intelligence"...
A closely guarded, high-tech facility that Elon Musk is building in Memphis...
A paradigm-shift that could add as much as $23 trillion to the global economy...
And a new passive income stream that Elon Musk says could help you earn up to $30,000-$50,000 a year with minimal effort.
I've identified the stock at center of this megatrend – and I'm giving away its name and ticker symbol FOR FREE.
Click here to access your free pick now.
If you buy just one stock in 2026, I urge you to make it this one.
I'll also show you a 30-second demo of this technology – so you can see why Nvidia CEO Jensen Huang said, "This is superhuman. It's never been done before."
In addition, I'll provide proof that I'm investing $358 million of my own firm's money in the outcome of this radical transformation.
We're talking about a MAJOR upgrade to the artificial intelligence revolution that could make you 10X your money or more.
See the demo for yourself, right here.
Regards,
Louis Navellier
Senior Investment Analyst, InvestorPlace
P.S. By the way, a 10X gain may be a conservative estimate. In fact, if you had invested $1,000 in Nvidia when I recommended it in 2005 and held on, you would have $770,250 today. That's the size of the opportunity I'm sharing with you today. Click here to get the name and ticker symbol of the stock at the center of it all.
Viking Therapeutics: The High-Stakes Weight Loss Contender
By Jeffrey Neal Johnson. Article Published: 2/26/2026.
Key Points
- The company has achieved significant clinical milestones by advancing both injectable and oral formulations of its lead weight loss candidate into late-stage trials.
- Strategic moves, including a major manufacturing agreement and the hiring of a seasoned commercial executive, demonstrate a strong commitment to future market readiness.
- Wall Street analysts project substantial upside for the stock as the company capitalizes on the immense demand for effective new treatments in the obesity sector.
- Special Report: [Sponsorship-Ad-6-Format3]
The pharmaceutical industry is experiencing a historic gold rush around obesity treatments. While giants like Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) dominate headlines and pharmacy shelves, the market is hungry for a third player to disrupt the status quo. Supply shortages and high prices have created a large opening for agile competitors, and Viking Therapeutics (NASDAQ: VKTX) has emerged as the most advanced clinical-stage challenger in the field.
Trading around $34 as of late February, Viking represents a distinct alternative for investors. It is not a stable, dividend-paying giant—it is a high-beta growth play. That means the stock has materially greater volatility than the broader sector, but also a correspondingly higher potential upside. Viking sits at a crossroads, balancing the possibility of a sizable buyout premium against the operational risks of taking on the world's largest drugmakers.
The Weapon of Choice: Speed and Differentiation
Have $500? Invest in Elon's AI Masterplan (Ad)
What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO.
Viking's lead asset is VK2735, a dual agonist that targets GLP-1 and GIP receptors. That biology mirrors some of the most effective treatments available today, such as Zepbound, but Viking is advancing its program at a pace that sets it apart from many clinical-stage biotechs and supports the case for real commercial demand.
The company recently completed enrollment for its Phase 3 VANQUISH-1 obesity trial, surpassing its target of 4,500 patients ahead of schedule. This rapid enrollment signals both strong patient demand for alternatives and investigator enthusiasm for Viking's molecule. VANQUISH-2, which focuses on obesity in patients with Type 2 diabetes, is also nearing full enrollment in the first quarter of 2026.
Another potential differentiator is the oral formulation of VK2735. In Phase 2 trials the oral drug demonstrated up to 12.2% weight loss, and Phase 3 trials are scheduled to begin in the third quarter of 2026. Most current treatments require weekly injections, which can be a barrier for many patients. Viking is one of the few companies developing a dual agonist in both injectable and oral forms, enabling a flexible treatment paradigm:
- Induction: Rapid weight loss via injection.
- Maintenance: Daily oral therapy to sustain that weight loss.
This flexibility could keep patients within the Viking ecosystem throughout treatment, a clear competitive advantage over single-format therapies.
Built to Buy or Built to Last?
Wall Street has long speculated that Viking is a prime takeover target for a major pharmaceutical company seeking entry into the obesity market. Management, however, appears to be pursuing a dual-track strategy: positioning the company to be an attractive acquisition while also building the infrastructure to launch independently.
That intent is evident in recent hires. In January 2026, Viking appointed Neil Aubuchon as Chief Commercial Officer. Aubuchon spent nearly 17 years at Eli Lilly (NYSE: LLY), a direct competitor; his move to Viking suggests confidence in the pipeline's commercial prospects.
Viking also signed a comprehensive agreement with CordenPharma to support commercial-scale manufacturing of VK2735. Securing a top-tier manufacturing partner is critical given that market leaders have struggled with supply constraints. Small biotech failures often stem not from efficacy issues but from an inability to produce sufficient drug supply.
By pairing manufacturing capacity with experienced commercial leadership, Viking reduces execution risk. That creates leverage: an acquirer would be buying not just a molecule but a near-turnkey commercial operation, which could force suitors to pay a meaningful premium if a deal were sought.
Burning Cash to Build Value
Biotech growth is expensive, and Viking's financials reflect that ambition. In its fourth-quarter earnings report released in February 2026, the company reported a loss of $1.38 per share, missing analyst estimates of a $0.89 loss. The wider loss was driven mainly by Research and Development (R&D), which rose to $345 million for the fiscal year, up from $101.6 million the prior year.
Investors should view this spending in context: the cash is funding large, simultaneous Phase 3 programs. Viking also maintains a solid balance sheet with two key strengths:
- Liquidity: $706 million in cash, cash equivalents, and short-term investments.
- Runway: That cash is expected to fund the company through its major 2026 data readouts, reducing the immediate need for dilutive financing.
Despite progress, skepticism remains. As of late January 2026, short interest in Viking was about 26 million shares, roughly 24.04% of the float. That level of shorting creates a volatile dynamic.
Short sellers are wagering the stock will fall. But if Viking delivers positive news—completion of VANQUISH-2 enrollment or an IND filing for a new amylin agonist, for example—shorts may be forced to cover quickly, generating significant buying pressure and a potential short squeeze.
The gap between market sentiment and analyst expectations is notable. While the stock traded in the mid-$30s, the average analyst price target was $87.80, implying more than 150% upside if Viking executes its plan successfully.
The Final Weigh-In: Risk Meets Reward
Viking Therapeutics is a high-stakes opportunity in a lucrative area of medicine. It offers exposure to the obesity drug revolution and the potential to become a major player either through a buyout or a successful independent launch.
The company has moved from early-stage research into late-stage execution: VANQUISH-1 is fully enrolled and the oral program is advancing toward Phase 3. At the same time, securing manufacturing capacity and commercial leadership provides a buffer if an acquisition does not occur.
That said, the path remains volatile. Viking's stock reacts strongly to news from larger competitors, and heavy short interest promises a bumpy ride. For investors with a higher tolerance for risk, the company's cash position and advanced clinical programs present a compelling thesis. The next immediate catalyst to watch is the expected completion of enrollment in the VANQUISH-2 diabetes trial later this quarter.
Zillow's 3-Day Rally Could Mean More Than You Think
Submitted by Sam Quirke. Publication Date: 2/21/2026.
Key Points
- Zillow has fallen back to 2014 price levels after a brutal multi-year slide, erasing nearly two years of gains.
- The stock has just logged three consecutive up days for the first time in weeks, while the RSI is at one of its lowest levels in more than a decade.
- Revenue growth, margin expansion, and a fresh Overweight rating with more than 50% upside suggest pessimism may be overdone.
- Special Report: [Sponsorship-Ad-6-Format3]
After months of relentless selling, shares of Zillow Group Inc (NASDAQ: ZG) have quietly done something they hadn't managed in weeks: three straight days of gains. That may not sound dramatic, but after nearly a 50% collapse and extreme bearish sentiment, it's notable.
Shares now trade around $45 — roughly where they were in 2014 — after nearly two years of gains were erased over the past five months. A sluggish housing market, elevated mortgage rates, and a disappointing report last week have weighed on the stock. Yet with sentiment as negative as it is and price action showing early signs of stabilization, could this run of green days be the start of a recovery?
The Fundamentals Don't Match the Fear
Have $500? Invest in Elon's AI Masterplan (Ad)
What if you could claim a stake in what's set to be the biggest IPO ever… starting with just $500?
Everyone is talking about Elon Musk's SpaceX IPO.
The latest earnings report may have accelerated the slide, but it didn't start it — Zillow shares have been under pressure since September. Still, last week's results were far from disastrous. Earnings missed by a few cents, but revenue beat expectations and grew 18% year over year.
Adjusted EBITDA rose year over year and margins expanded, helping the company reach full-year profitability. The chart may look grim, but this wasn't the performance you'd expect from a business in terminal decline.
One standout from the quarter was strength in rentals. That segment delivered robust growth — particularly in multifamily — and management expects expansion to continue next year. Rentals are now a critical pillar of Zillow's diversification strategy.
Mortgage revenue also expanded meaningfully, reinforcing Zillow's broader evolution into an integrated ecosystem spanning buying, selling, renting, and financing. The strategy increasingly aims to capture value across the entire moving journey rather than relying solely on listing fees.
Investor Worries May Be Overblown
Part of the recent slide reflects anxiety about AI disruption and private listing networks. Some investors fear AI-powered portals could erode Zillow's dominance. This concern affects not just Zillow but the wider tech sector.
But consumer behavior suggests Zillow will remain the default home-search destination for the foreseeable future. Competitors may be spending aggressively to gain share, but they've had limited success to date.
Housing at a Cyclical Low
Zillow still faces an uphill battle in the near term. The broader U.S. housing market remains near a cyclical trough due to elevated mortgage rates and affordability constraints. Transaction volumes are subdued, creating a challenging backdrop for any real estate-linked platform.
However, cyclical troughs can create opportunities for investors willing to take risk. When transactions normalize and the market picks up again, Zillow's diversified revenue base and improved margins should position it well. At current price levels, the market appears to be pricing in prolonged stagnation — which may prove overly pessimistic.
Technicals and Analyst Support Align
Technically, the stock is deeply oversold, which supports the case for buying the dip. Zillow's relative strength index (RSI) currently sits around 24 — its lowest reading in more than a decade. That signals extreme selling pressure that rarely persists indefinitely without at least a relief rally.
While this week's three-day run of gains doesn't confirm a full reversal, it does suggest selling pressure may be starting to exhaust itself. When multi-year lows coincide with extreme oversold readings and improving price action, contrarian investors take notice.
Analysts are starting to take notice: Piper Sandler reiterated its Overweight rating last week and set a $70 price target — implying more than 50% upside from current levels.
Is This a Buy Signal?
Any stock exiting a 50% slide carries risk, and Zillow is no different. If mortgage rates remain elevated for an extended period and housing continues to stagnate, earnings could stay pressured. The market's reaction to last week's miss and management's cautious guidance suggests investors will be sensitive to any signs of slowing momentum in the quarters ahead.
For investors willing to tolerate that risk, the opportunity may be compelling. Improving price action, extreme oversold technicals, continued revenue growth, and analyst upside form a persuasive case. Expectations are low, sentiment is washed out, and the stock trades at decade-old levels.
Three consecutive up days may not prove the bottom is in. But after a 50% slide, it may be one sign that the market is beginning to view Zillow with fresh eyes.
This email communication is a sponsored email from InvestorPlace, a third-party advertiser of InsiderTrades.com and MarketBeat.
If you have questions or concerns about your account, please don't hesitate to contact our South Dakota based support team at contact@marketbeat.com.
If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.
Copyright 2006-2026 MarketBeat Media, LLC.
345 N Reid Place, Suite 620, Sioux Falls, South Dakota 57103. USA..
No comments:
Post a Comment